News
Blueprint Medicines acquires Lengo Therapeutics and with it LNG 451 , a therapy for treatment of NSCLC in patients with EGFR exon 20 insertion mutations.
Blueprint Medicines Corporation announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG 451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 insertion mutations.
An investigational new drug (IND) application for LNG-451 was submitted to the FDA by Lengo Therapeutics in December 2021.
As previously disclosed, under the terms of the agreement, Blueprint Medicines acquired Lengo Therapeutics for $250 million in cash plus up to $215 million in additional potential payments based on the achievement of certain regulatory approval and sales-based milestones.
Condition: NSCLC / EGFR
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.